Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40536 | 0.84 | ALDH1A1 (0.54) | KDM4EALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL4096953 | 0.83 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL146560 | 0.83 | TSHR (0.63) | KDM4EALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL1189439 | 0.81 | TSHR (0.45) | KDM4EALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL112377 | 0.80 | TSHR (0.65) | KDM4EALDH1A1LMNAKMT2AATM | |
| SCHEMBL29787113 | 0.80 | TSHR (0.65) | KDM4EALDH1A1LMNAKMT2AATM | |
| SCHEMBL29843413 | 0.79 | CES2 (0.65) | KDM4EALDH1A1LMNAKMT2AATM | |
| SCHEMBL263770 | 0.79 | CES2 (0.65) | KDM4EALDH1A1LMNAKMT2AATM | |
| SCHEMBL4878766 | 0.78 | TSHR (0.63) | KDM4EALDH1A1LMNAKMT2AATM | |
| SCHEMBL11825925 | 0.78 | PKM (0.39) | KDM4EALDH1A1LMNAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3931317-A | FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3964509-B1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO LTD (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20220213085-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| CN-101460490-A | Substituted ring fused azines and their use in cancer therapy | AUCKLAND UNISERVICES LTD (NZ) | 2009-06-17 | — | — | CN | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| EP-0263523-B1 | Process for the preparation of thiazolo [2,3-b] quinazolones | BASF AG (DE) | 1993-12-29 | — | — | EP | disclosed |
| US-5030727-A | Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0263523-A2 | Process for the preparation of thiazolo [2,3-b] quinazolones | BASF Aktiengesellschaft (DE) | 1988-04-13 | — | — | EP | disclosed |
| US-4400507-A | FOR COLORING POLYMERS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1983-08-23 | — | — | US | disclosed |
| US-4262120-A | YELLOW TO ORANGE SHADES OF GOOD FASTNESS | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| US-3931317-A | FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | KDM4E 2486/4885ALDH1A1 203/4885LMNA 172/4885 |
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | KDM4E 3982/4885ALDH1A1 587/4885LMNA 3612/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | KDM4E 2486/4885ALDH1A1 203/4885LMNA 172/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | KDM4E 2586/4885ALDH1A1 65/4885LMNA 1348/4885 |
| US-20220213085-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HLA-B, HLA-A, SLC10A1 | KDM4E 2312/4885ALDH1A1 2801/4885LMNA 320/4885 |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | HLA-B, HLA-A, SLC10A1 | KDM4E 2312/4885ALDH1A1 2801/4885LMNA 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.